LON:LABS Life Science REIT (LABS) Share Price, News & Analysis GBX 42.78 -0.23 (-0.52%) As of 11:12 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock About Life Science REIT Stock (LON:LABS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Life Science REIT alerts:Sign Up Key Stats Today's Range 42.50▼ 42.7850-Day Range 41.20▼ 48.6052-Week Range 31.30▼ 49Volume342,531 shsAverage Volume762,925 shsMarket Capitalization£151.86 millionP/E RatioN/ADividend Yield4.68%Price TargetGBX 46.50Consensus RatingModerate Buy Company Overview Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange. The registered office of the Company is located at 6th Floor, 65 Gresham Street, London, EC2V 7NQ. Read More Life Science REIT Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreLABS MarketRank™: Life Science REIT scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingLife Science REIT has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLife Science REIT has received no research coverage in the past 90 days.Read more about Life Science REIT's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Life Science REIT is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Life Science REIT is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLife Science REIT has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for LABS. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipLife Science REIT is a leading dividend payer. It pays a dividend yield of 5.67%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthLife Science REIT does not have a long track record of dividend growth.Read more about Life Science REIT's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for LABS. News and Social Media2.6 / 5News SentimentN/A News SentimentLife Science REIT has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Real Estate companies.News Coverage This WeekMarketBeat has tracked 1 news article for Life Science REIT this week, compared to 0 articles on an average week.Search Interest1 people have searched for LABS on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Life Science REIT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.96% of the stock of Life Science REIT is held by insiders.Percentage Held by Institutions67.27% of the stock of Life Science REIT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Life Science REIT's insider trading history. Receive LABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Life Science REIT and its competitors with MarketBeat's FREE daily newsletter. Email Address LABS Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com LABS Stock Analysis - Frequently Asked Questions How have LABS shares performed this year? Life Science REIT's stock was trading at GBX 38 at the beginning of the year. Since then, LABS shares have increased by 12.2% and is now trading at GBX 42.63. How were Life Science REIT's earnings last quarter? Life Science REIT plc (LON:LABS) issued its quarterly earnings data on Wednesday, April, 16th. The company reported $1.70 earnings per share (EPS) for the quarter. Life Science REIT had a negative trailing twelve-month return on equity of 14.53% and a negative net margin of 198.99%. How do I buy shares of Life Science REIT? Shares of LABS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings4/16/2025Today7/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorReal Estate Industry REIT - Healthcare Facilities Sub-IndustryN/A Current SymbolLON:LABS CIKN/A Webwww.lifesciencereit.co.uk Phone44-20-7945-9566FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Life Science REITGBX 46.50 High Price TargetGBX 57 Low Price TargetGBX 36 Potential Upside/Downside+8.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)GBX (11.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£40.62 million Net Margins-198.99% Pretax MarginN/A Return on Equity-14.53% Return on Assets1.25% Debt Debt-to-Equity Ratio44.18 Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales£20.41 million Price / Sales7.44 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 76.35 per share Price / Book0.56Miscellaneous Outstanding Shares355,028,736Free FloatN/AMarket Cap£151.95 million OptionableNot Optionable Beta0.08 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:LABS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredMajor Rollout of Social Security X?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Life Science REIT plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Life Science REIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.